Tag:
ImmunoGen
Latest Headlines
Latest Headlines
Genentech nabs FDA approval for T-DM1 cancer killer
Roche's Genentech picked up FDA approval for its late-stage breast cancer therapy Kadcyla, formerly T-DM1, which uses antibodies to deliver cancer drugs directly to the offending cells.
Targacept taps Stephen A. Hill to serve as president and CEO
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Roche, ImmunoGen gain speedy review for T-DM1 breast cancer breakthrough
Roche has gained the inside track in the final lap of a long and expensive race to win an FDA approval for the armed antibody T-DM1, a new approach to treating HER2-positive breast cancer that marks a significant advance for patients.
Roche, ImmunoGen's T-DM1 boosts cancer survival
Roche and ImmunoGen's trastuzumab emtansine (T-DM1) slashed the risk of death by almost a third compared with standard treatment in the EMILIA Phase III trial in women with advanced breast cancer.
UPDATED: T-DM1 survival rate wows as Roche pushes for megablockbuster approval
Investigators behind the big T-DM1 breast cancer program took the lid off the last big data box from its pivotal study this morning, revealing that the armed antibody delivered a 32% reduction in the risk of death among patients in the pivotal Phase III study when compared to the standard-of-care arm.
ImmunoGen celebrates T-DM1 Phase III success with market plans
ImmunoGen's ($IMGN) antibody-drug conjugate (ADC) trastuzumab emtansine (T-DM1) has significantly improved survival in a Phase III trial in women with advanced breast cancer, and the agent has been submitted for marketing approval.
ImmunoGen rises on hopes for encores to Roche's armed breast cancer drug
A Cowen & Company analyst argued Wednesday that investors haven't given much credit to ImmunoGen's other drug candidates, and his assessment preceded a bump in the company's stock price.
$27M funding will help advance Mersana's ADC pipeline
Mersana Therapeutics has raised $27 million in a Series A-1 financing led by new investor New Enterprise Associates (NEA), and will use the money to continue development of its Fleximer antibody-drug conjugate (ADC) platform and other ADCs. This is the first biopharma investment from NEA's recently announced $2.6 billion NEA 14 fund.
ASCO spotlight: Antibody-drug conjugates arrive
The past year has been one worth celebrating for developers of antibody-drug conjugates (ADCs), which are drugs that marry an anti-cancer toxin to a targeted antibody to kill tumors with fewer side effects than traditional treatments.
Is ImmunoGen overvalued?
The drug delivery company may not be worth the $1.2 billion its investors would believe.
